<DOC>
	<DOCNO>NCT01280123</DOCNO>
	<brief_summary>This multi-center , double-blind , placebo control clinical trial two dosage oral pioglitazone ( 15 milligram ( mg ) 45 milligram ( mg ) ) safety , tolerability , futility . Subjects stable dose rasagiline 1 mg/day selegiline 10 mg/day least 8 week 8 month , randomize one two dosage oral pioglitazone ( 15 mg 45 mg ) match placebo . The study measure disease progression change total Unified Parkinson 's Disease Rating Scale ( UPDRS ) score baseline visit 44 week .</brief_summary>
	<brief_title>Pioglitazone Early Parkinson 's Disease</brief_title>
	<detailed_description>A Multi-Center , Double-Blind , Placebo-Controlled Phase II Study Pioglitazone Early Parkinson 's Disease ( PD ) . The patient population early stage PD ( &lt; 5 year diagnosis ) , must treat 1 mg/day rasagiline 10 mg/day selegiline least 8 week 8 month prior enrollment . The primary objective clinical trial ass futility pioglitazone PD disease progression measure change total UPDRS score baseline visit 44 week . The secondary objective study collect additional efficacy safety/tolerability data use plan subsequent Phase III trial pioglitazone early , treat PD . Measures cognition , mood blood- urine-based biomarkers also explore . Subjects trial randomly assign 1:1:1 ratio one three study arm : 15 mg , 45 mg placebo .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Willing able give inform consent . 2 . Men woman idiopathic PD le 5 year duration diagnosis Hoehn Yahr Stage &lt; 2 . 3 . On stable dosage rasagiline 1 mg/day selegiline 10 mg/day least 8 week 8 month prior baseline . Expected remain stable dose rasagiline selegiline treatment PD duration study ( 44 week ) . 4 . Diagnosis must confirm bradykinesia plus one cardinal sign ( rest tremor , rigidity ) present , without know suspected cause parkinsonism . The clinical sign must asymmetric . 5 . Subjects may take stable dos ( 30 day ) anticholinergic creatine ( &lt; 5gm/day ) must expect remain dose . 6 . Age &gt; 30 year . 7 . Women postmenopausal surgically sterile must use medically accepted contraceptive regimen least 60 day baseline visit , agree continue use throughout duration study 30 day final dose study drug . 1 . Exposure dopaminergic PD therapy amantadine within 60 day prior baseline visit 90 day point past 2 . Use follow drug within 180 day prior baseline : neuroleptic , metoclopramide , alphamethyldopa , clozapine , olanzapine flunarizine . 3 . Use follow drug within 90 day prior baseline : methylphenidate , cinnarizine , reserpine , tetrabenazine , amphetamine monoamine oxidase ( MAO ) A inhibitor ( pargyline , phenelzine , tranylcypromine ) . 4 . Presence druginduced parkinsonism ( e.g. , metoclopramide , flunarizine ) , metabolic identify neurogenetic disorder ( e.g. , Wilson 's disease ) , encephalitis , atypical Parkinsonian syndrome ( e.g. , progressive supranuclear palsy , multiple system atrophy ) . 5 . Participation drug study receipt investigational drug within 30 day prior baseline study . 6 . Presence freezing . 7 . Any clinically significant psychiatric medical condition laboratory abnormality , would judgment Investigator interfere subject 's ability participate . 8 . History stereotaxic brain surgery PD 9 . Clinically significant structural brain disease investigator believe would interfere study evaluation . 10 . History congestive heart failure . 11 . Use pioglitazone rosiglitazone within 90 day randomization . 12 . Known intolerance pioglitazone rosiglitazone . 13 . Allergy rasagiline selegiline , contraindication rasagiline selegiline use . 14 . Type I Type II diabetes mellitus . 15 . HgbA1C great equal 6 % Screening . 16 . Known liver disease elevation AST ALT great 2.5 time upper limit normal . 17 . Known history osteoporosis . All woman â‰¥ 65 year age men woman high risk osteoporosis document evidence screen osteoporosis . Factors associate high risk osteoporosis include : previous non traumatic fracture , chronic glucocorticoid use , body weight 58 kg , family history hip fracture , current cigarette smoking , excessive alcohol intake . 18 . Drug alcohol use dependence , opinion Investigator , would interfere safe conduct study . 19 . Significant peripheral edema ( 2+ ) extremity etiology . 20 . Current plan use gemfibrozil rifampin trial . 21 . History bladder cancer . 22 . Evidence hematuria evaluate evidence bladder cancer . ( Documentation work repeat urine test negative hematuria primary care physician urologist feel work require . ) 23 . History macular edema .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Biomarkers</keyword>
</DOC>